Chemed Corp (CHE) stock

CHENYSEServices-Home Health Care ServicesFiscal year ends December 31

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 17/305% above fair value

$550.20−0.42 (-0.08%)

Close on Nov 12, 2026Market cap $7.16BP/E 26.3Yield 0.40%

Earnings

Chemed's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.

Next report

Feb 24, 2027

Q4 FY2026 · estimated, after the close

Revenue, Q3 FY2026

$690.90M

+10.6% on a year earlier

Adjusted Diluted EPS, Q3 FY2026

$6.75

$5.27 a year earlier

Latest guidance

Raised

Jul 28, 2026 · 3 items

Quarterly results

Revenue and earnings per share from each of Chemed's earnings releases, newest first

Quarter	Reported	Revenue	YoY	EPS	Adj. EPS	Source
Q4 FY2026ended Dec 31, 2026	Feb 24, 2027Expected	–	–	–	–	–
Q3 FY2026ended Sep 30, 2026	Oct 27, 2026after the close	$690.90M	+10.6%	$5.45	$6.75	Release
Q2 FY2026ended Jun 30, 2026	Jul 28, 2026after the close	$673.30M	+8.8%	$5.13	$6.06	Release
Q1 FY2026ended Mar 31, 2026	Apr 23, 2026after the close	$657.50M	+1.6%	$4.84	$5.65	Release
Q4 FY2025ended Dec 31, 2025	Feb 25, 2026after the close	$639.30M	-0.1%	$5.48	$6.42	Release
Q3 FY2025ended Sep 30, 2025	Oct 28, 2025after the close	$624.90M	+3.1%	$4.46	$5.27	Release
Q2 FY2025ended Jun 30, 2025	Jul 29, 2025after the close	$618.80M	+3.8%	$3.57	$4.27	Release
Q1 FY2025ended Mar 31, 2025	Apr 23, 2025after the close	$646.90M	+9.8%	$4.86	$5.63	Release
Q4 FY2024ended Dec 31, 2024	Feb 26, 2025after the close	$640.00M	+9.2%	$6.02	$6.83	Release
Q3 FY2024ended Sep 30, 2024	Oct 29, 2024after the close	$606.20M	+7.3%	$5.00	$5.64	Release
Q2 FY2024ended Jun 30, 2024	Jul 24, 2024after the close	$595.90M	+7.6%	$4.65	$5.47	Release
Q1 FY2024ended Mar 31, 2024	Apr 24, 2024after the close	$589.20M	+5.2%	$4.24	$5.20	Release
Q4 FY2023ended Dec 31, 2023	Feb 27, 2024after the close	$585.90M	+7.1%	$5.90	$6.60	Release
Q3 FY2023ended Sep 30, 2023	Oct 25, 2023after the close	$565.00M	+7.4%	$4.93	$5.32	Release
Q2 FY2023ended Jun 30, 2023	Jul 26, 2023after the close	$554.00M	+4.3%	$3.51	$4.71	Release
Q1 FY2023ended Mar 31, 2023	Apr 26, 2023after the close	$560.00M	+5.5%	$3.58	$4.82	Release
Q4 FY2022ended Dec 31, 2022	Feb 23, 2023after the close	$547.00M	+1.1%	$4.13	$5.39	Release
Q3 FY2022ended Sep 30, 2022	Oct 31, 2022after the close	$526.00M	-2.4%	$3.78	$4.74	Release
Q2 FY2022ended Jun 30, 2022	Jul 27, 2022after the close	$531.00M	–	$4.40	$4.84	Release
Q1 FY2022ended Mar 31, 2022	Apr 26, 2022after the close	$531.00M	–	$4.22	$4.79	Release
Q4 FY2021ended Dec 31, 2021	Feb 24, 2022after the close	$541.00M	–	$4.81	$5.25	Release
Q3 FY2021ended Sep 30, 2021	Oct 28, 2021after the close	$539.00M	–	$4.55	$5.06	Release
Q2 FY2021ended Jun 30, 2021	Jul 27, 2021after the close	–	–	–	–	Filing
Q1 FY2021ended Mar 31, 2021	Apr 27, 2021after the close	–	–	–	–	Filing
Q4 FY2020ended Dec 31, 2020	Feb 23, 2021after the close	–	–	–	–	Release
Q3 FY2020ended Sep 30, 2020	Oct 29, 2020after the close	–	–	–	–	Filing

Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.

Current guidance

Chemed's latest outlook for periods it has not reported yet, compared with what it said before

Metric	Period	Guidance	Before	Change	Given
anticipated revenue growth	FY2026	+3% – +3.5%	+3% – +3.5%	Reaffirmed	Jul 28, 2026
Anticipated revenue growth, excluding the impact of the Medicare Capnon-GAAP	FY2026	+6.5% – +7.5%	–	New	Apr 23, 2026
revenue	FY2026	$5.00M – $5.50M	–	New	Apr 23, 2026
adjusted EBITDA marginnon-GAAP	FY2026	21.5% – 22.5%	22.5% – 23%	Lowered	Jul 28, 2026
Full year EBITDA margin, prior to Medicare Cap	FY2026	17.5% – 18%	–	New	Feb 25, 2026
earnings per diluted share, excluding non-cash expenses for stock options, tax benefits from stock option exercises, costs related to litigation and other discrete itemsnon-GAAP	FY2026	$25.00 – $25.75	$24.00 – $24.75	Raised	Jul 28, 2026
ADC	FY2026	+3.5% – +4%	–	New	Feb 25, 2026
anticipated ADC growthnon-GAAP	FY2026	+4.5% – +5.5%	–	New	Apr 23, 2026
Estimated adjusted EBITDA marginnon-GAAP	FY2026	21.5% – 22.5%	–	Raised	Apr 23, 2026
Medicare Cap billing limitations	FY2026	$9.50M	–	New	Feb 25, 2026
revised EBITDA margin, excluding the impact of the Medicare Capnon-GAAP	FY2026	18% – 18.5%	–	New	Apr 23, 2026

Guidance vs results

The last range Chemed gave before each report, against the figure it then reported. Full years add up the four quarters.

Period	Metric	Guidance	Actual	Result
FY2025	per share	$22.00 – $22.30	$21.59Σ4Q	Below range

Guidance history

Every forecast Chemed put in an earnings release, newest first

Given	Metric	Period	Guidance	Change
Jul 28, 2026	earnings per diluted share, excluding non-cash expenses for stock options, tax benefits from stock option exercises, costs related to litigation and other discrete items	FY2026	$25.00 – $25.75	Raised
Jul 28, 2026	adjusted EBITDA margin	FY2026	21.5% – 22.5%	Lowered
Jul 28, 2026	anticipated revenue growth	FY2026	+3% – +3.5%	Reaffirmed
Apr 23, 2026	earnings per diluted share, excluding non-cash expenses for stock options, tax benefits from stock option exercises, costs related to litigation and other discrete items	FY2026	$24.00 – $24.75	Raised
Apr 23, 2026	revised EBITDA margin, excluding the impact of the Medicare Cap	FY2026	18% – 18.5%	New
Apr 23, 2026	Estimated adjusted EBITDA margin	FY2026	21.5% – 22.5%	Raised
Apr 23, 2026	anticipated ADC growth	FY2026	+4.5% – +5.5%	New
Apr 23, 2026	anticipated revenue growth	FY2026	+3% – +3.5%	Reaffirmed
Apr 23, 2026	Anticipated revenue growth, excluding the impact of the Medicare Cap	FY2026	+6.5% – +7.5%	New
Apr 23, 2026	revenue	FY2026	$5.00M – $5.50M	New
Feb 25, 2026	earnings per diluted share, excluding non-cash expenses for stock options, tax benefits from stock option exercises, costs related to litigation and other discrete items	FY2026	$23.25 – $24.25	New
Feb 25, 2026	Full year EBITDA margin, prior to Medicare Cap	FY2026	17.5% – 18%	New
Feb 25, 2026	adjusted EBITDA margin	FY2026	22.5% – 23%	New
Feb 25, 2026	ADC	FY2026	+3.5% – +4%	New
Feb 25, 2026	Medicare Cap billing limitations	FY2026	$9.50M	New
Feb 25, 2026	revenue growth	FY2026	+3% – +3.5%	Lowered
Feb 25, 2026	VITAS 2026 revenue, prior to Medicare Cap	FY2026	+5.5% – +6.5%	New
Oct 28, 2025	per share	FY2025	$22.00 – $22.30	New
Jul 29, 2025	earnings per diluted share, excluding non-cash expense for stock options, tax benefits from stock option exercises, costs related to litigation and other discrete items	FY2025	$22.00 – $22.30	Lowered
Jul 29, 2025	adjusted EBITDA margin, prior to Medicare Cap	FY2025	18.2% – 18.7%	New
Jul 29, 2025	adjusted EBITDA margin	FY2025	23.5% – 24.5%	Raised
Jul 29, 2025	Medicare Cap billing limitations	FY2025	$28.20M	Raised
Jul 29, 2025	revenue increase	FY2025	+1.25% – +1.75%	Lowered
Jul 29, 2025	revenue, prior to Medicare Cap	FY2025	+7.5% – +8.5%	New
Feb 26, 2025	earnings per diluted share, excluding: non-cash expense for stock options, tax benefits from stock option exercises, costs related to litigation, and other discrete items	FY2025	$24.95 – $25.45	New
Feb 26, 2025	adjusted EBITDA margin	FY2025	25.7% – 26.3%	Raised
Feb 26, 2025	adjusted EBITDA margin, prior to Medicare Cap	FY2025	18.4% – 18.9%	New
Feb 26, 2025	ADC	FY2025	+8.5% – +9%	New
Feb 26, 2025	Medicare Cap billing limitations	FY2025	$9.50M	New
Feb 26, 2025	revenue, prior to Medicare Cap	FY2025	+10.5% – +11.3%	New
Feb 26, 2025	revenue growth	FY2025	+2.4% – +3%	Lowered
Oct 29, 2024	earnings per diluted share, excluding non-cash expense for stock options, tax benefits from stock option exercises, costs related to litigation and other discrete items	FY2024	$23.00 – $23.15	Lowered
Jul 24, 2024	adjusted EBITDA attributable to Covenant Health	FY2024	$8.00M – $8.50M	New
Jul 24, 2024	full-year 2024 earnings per diluted share, excluding non-cash expense for stock options, tax benefits from stock option exercises, costs related to litigation and other discrete items	FY2024	$23.55 – $23.80	Raised
Jul 24, 2024	diluted share count	FY2024	15.25	New
Jul 24, 2024	Full year adjusted EBITDA margin, prior to Medicare Cap	FY2024	19.3% – 19.7%	New
Jul 24, 2024	Roto-Rooter adjusted EBITDA margin	FY2024	26.5% – 27%	Raised
Jul 24, 2024	effective corporate tax rate on adjusted earnings	FY2024	24.3%	Lowered
Jul 24, 2024	ADC	FY2024	+13.3% – +14.4%	New
Jul 24, 2024	Medicare Cap billing limitations	FY2024	$8.50M	New
Jul 24, 2024	adjusted net income attributable to Covenant Health	FY2024	$5.50M – $6.00M	New
Jul 24, 2024	Roto-Rooter revenue decline	FY2024	+4% – +5%	New
Jul 24, 2024	VITAS 2024 revenue, prior to Medicare Cap	FY2024	+16.3% – +17.3%	New
Jul 24, 2024	Covenant Health revenue contribution	FY2024	$30.00M – $32.00M	New
Apr 24, 2024	earnings per diluted share, excluding: non-cash expense for stock options, tax benefits from stock option exercises, costs related to litigation, and other discrete items	FY2024	$23.30 – $23.70	Reaffirmed
Feb 27, 2024	earnings per diluted share, excluding: non-cash expense for stock options, tax benefits from stock option exercises, costs related to litigation, and other discrete items	FY2024	$23.30 – $23.70	New
Oct 25, 2023	earnings per diluted share, excluding: non-cash expense for stock options, tax benefits from stock option exercises, costs related to litigation, and other discrete items	FY2023	$19.82 – $20.02	Lowered
Jul 26, 2023	adjusted EBITDA margin, prior to Medicare Cap and accrued retention bonuses related to the hiring initiatives	FY2023	16.5% – 17%	Lowered
Jul 26, 2023	adjusted EBITDA margin	FY2023	28% – 28.5%	Raised
Jul 26, 2023	earnings per diluted share, excluding: non-cash expense for stock options, tax benefits from stock option exercises, costs related to litigation, retention program for licensed healthcare employees, a	FY2023	$19.90 – $20.10	Lowered
Jul 26, 2023	diluted share count	FY2023	15.2	Raised
Jul 26, 2023	effective corporate tax rate on adjusted earnings	FY2023	24.7%	Lowered
Jul 26, 2023	ADC	FY2023	+6.5% – +7.5%	Raised
Jul 26, 2023	Medicare Cap billing limitations	FY2023	$11.00M	Reaffirmed
Jul 26, 2023	revenue growth	FY2023	+1% – +2%	New
Jul 26, 2023	VITAS 2023 revenue, prior to Medicare Cap	FY2023	+8.5% – +9.5%	Raised
Feb 23, 2023	adjusted EBITDA margin, prior to Medicare Cap and accrued retention bonuses related to the hiring initiatives announced last year	FY2023	16.3% – 16.6%	New
Feb 23, 2023	adjusted EBITDA margin	FY2023	29.3% – 29.5%	Raised
Feb 23, 2023	earnings per diluted share, excluding non-cash expense for stock options, tax benefits from stock option exercises, costs related to litigation, retention program for licensed healthcare employees, an	FY2023	$20.75 – $21.10	New
Feb 23, 2023	diluted share count	FY2023	15	New
Feb 23, 2023	effective corporate tax rate on adjusted earnings	FY2023	25.1%	New
Feb 23, 2023	ADC	FY2023	+3.5% – +4%	New
Feb 23, 2023	Medicare Cap billing limitations	FY2023	$11.00M	New
Feb 23, 2023	revenue growth	FY2023	+5% – +5.5%	New
Feb 23, 2023	revenue, prior to Medicare Cap	FY2023	+6% – +7%	New
Oct 31, 2022	earnings per diluted share, excluding non-cash expense for stock options, tax benefits from stock option exercises, costs related to litigation, retention program for licensed healthcare employees, an	FY2022	$19.60 – $19.70	Raised
Jul 27, 2022	earnings per diluted share, excluding non-cash expense for stock options, tax benefits from stock option exercises, costs related to litigation and other discrete items	FY2022	$19.30 – $19.50	Raised
Feb 24, 2022	earnings per diluted share, excluding non-cash expense for stock options, tax benefits from stock option exercises, costs related to litigation and other discrete items	FY2022	$19.10 – $19.50	New
Oct 28, 2021	adjusted earnings per diluted share	FY2021	$19.00 – $19.20	New

Read from the company's earnings releases; each figure links to its sentence on hover. “Raised” and “Lowered” compare with the previous range for the same metric and period.